X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

A call to action on Overdose Awareness Day

By Guest Contributor  |    August 31, 2018
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Ask About Adherence: New study finds one-third of newly diagnosed diabetic patients aren’t starting treatment

By Guest Contributor  |    August 29, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Lauren Gilstrap, MD, MPH. ...   Read More

Number of value-based contracts continues to rise

By Michelle Drozd  |    August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...   Read More

Fact Check Friday: Getting the facts straight about negotiation in Medicare Part B

By Nicole Longo  |    August 24, 2018
Medicare Part B has been a hot topic in Washington, DC, this summer with an increasing number of conversations about how the program works. Unfortunately, a common misconception keeps popping up...   Read More

69 percent of patients abandon medicines when cost sharing is more than $250

By Holly Campbell  |    August 23, 2018
New research from the IQVIA Institute for Human Data Science shows that when cost sharing rises, patients are more likely to abandon their medicines. In 2017, 69 percent of commercially insured...   Read More

Ask About Adherence: Taking adherence research to a global level

By Guest Contributor  |    August 22, 2018
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we are pleased to share a blog post from Leah Zullig, PhD, MPH and Sabina De...   Read More

New analysis finds 340B medicine sales hit record high in 2017 and continue to grow as a share of total drug spending

By Nicole Longo  |    August 20, 2018
How big is the 340B program, and what share of the prescription medicine market does it represent? Those are popular questions of late as stakeholders discuss ways to improve the 340B program. In...   Read More

New analysis in Health Affairs reinforces one-third of medicine list price rebated back to supply chain

By Holly Campbell  |    August 13, 2018
An analysis published in a Health Affairs blog post by Nancy L. Yu, Preston Atteberry and Peter B. Bach of the Memorial Sloan Kettering Cancer Center reinforces that one-third of medicine list...   Read More

PhRMA member companies R&D investments hit record high in 2017 - $71.4 billion

By Tim McClung  |    August 9, 2018
PhRMA member companies invested $71.4 billion in research and development (R&D) in 2017, the highest level of investment on record, according to the 2018 PhRMA member annual survey, released in...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates